### First Approved Treatment for MASH Metabolic dysfunction-associated steatohepatitis (MASH) is a liver condition where excess fat builds up, leading to inflammation and scarring. The first drug approved to treat MASH is called Resmetirom (brand name Rezdiffra). This medication is specifically for adults with moderate to advanced liver scarring (stages F2 and F3 fibrosis). #### How Resmetirom Works Resmetirom targets a thyroid hormone receptor in the liver, changing how fat cells are processed. This helps reduce excess fat in the liver and can even reverse some of the scarring. In clinical trials, about 26% to 30% of people who took Resmetirom showed no signs of liver inflammation, compared to about 10% who only received lifestyle counseling. #### Benefits and Side Effects For around 25% of people, the liver scarring decreased by at least one stage. The drug also helped lower LDL cholesterol levels. Common side effects include diarrhea and nausea, but these are usually mild and go away on their own. Serious side effects are rare but can include liver damage and gallbladder issues. #### Usage and Monitoring Resmetirom is a once-daily pill that can be taken with or without food. Your doctor will monitor your liver enzymes closely, especially at the start of treatment. If you show signs of liver injury, you may need to stop the medication. #### Who Should Avoid It People with severe liver scarring (decompensated cirrhosis), pregnant or breastfeeding women should not take Resmetirom. It may also interact with other medications like statins, so consult your doctor. #### Cost and Availability The drug costs around $47,000 a year, but insurance may cover it. There are also assistance programs to help with costs. It's available from specialty pharmacies, and your doctor can help you get it if needed.